BioCentury | Jan 29, 2015
Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that could help treat inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP...
BioCentury | Sep 16, 2013
Company News

Bioniche cancer news

...Bioniche reached a settlement with dissident shareholders, former Biovail Corp. CEO William Wells and former Biovail SVP...
...of shareholders that together own over 5% of Bioniche shares. In the letter, the former Biovail...
BioCentury | Jul 15, 2013
Company News

Bioniche cancer news

...own benefit." Bioniche said the dissident shareholders are former Biovail Corp. CEO William Wells and former Biovail...
BioCentury | May 20, 2013
Company News

Bioniche cancer news

...Bioniche responded to an April 19 letter from former Biovail Corp. CEO William Wells and former Biovail...
...of shareholders that together own over 5% of Bioniche shares. In the letter, the former Biovail...
BioCentury | Apr 29, 2013
Company News

Bioniche cancer news

...Bioniche responded to an April 19 letter from former Biovail Corp. CEO William Wells and former Biovail...
...of shareholders that together own over 5% of Bioniche shares. In the letter, the former Biovail...
BioCentury | Mar 25, 2013
Clinical News

Pimavanserin: Additional Phase III data

...scores vs. placebo (p=0.001) (see BioCentury, Dec. 3, 2012). In 2009, Acadia and former partner Biovail Corp....
BioCentury | Dec 17, 2012
Finance

Maple leaf windfall

...the past five years was 2010's $4.8 billion combination of two Canadian plays: specialty pharma Biovail Corp....
BioCentury | Dec 3, 2012
Clinical News

Pimavanserin: Phase III data

...eligible to enroll in an open-label safety extension study. In 2009, Acadia and former partner Biovail Corp....
BioCentury | Dec 3, 2012
Clinical News

Bupropion regulatory update

...Indianapolis, Indiana) markets duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), as Cymbalta . Biovail Corp....
...U.S. since 2003, retained rights in the rest of the world except in Canada, where Biovail...
BioCentury | Nov 28, 2012
Clinical News

Acadia jumps on Phase III pimavanserin data

...patients with PDP. In 2009, Acadia fell 66% to $2 after it and former partner Biovail Corp....
...vs. placebo. The companies said the placebo response in the trial was higher than expected. Biovail...
Items per page:
1 - 10 of 603
BioCentury | Jan 29, 2015
Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that could help treat inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP...
BioCentury | Sep 16, 2013
Company News

Bioniche cancer news

...Bioniche reached a settlement with dissident shareholders, former Biovail Corp. CEO William Wells and former Biovail SVP...
...of shareholders that together own over 5% of Bioniche shares. In the letter, the former Biovail...
BioCentury | Jul 15, 2013
Company News

Bioniche cancer news

...own benefit." Bioniche said the dissident shareholders are former Biovail Corp. CEO William Wells and former Biovail...
BioCentury | May 20, 2013
Company News

Bioniche cancer news

...Bioniche responded to an April 19 letter from former Biovail Corp. CEO William Wells and former Biovail...
...of shareholders that together own over 5% of Bioniche shares. In the letter, the former Biovail...
BioCentury | Apr 29, 2013
Company News

Bioniche cancer news

...Bioniche responded to an April 19 letter from former Biovail Corp. CEO William Wells and former Biovail...
...of shareholders that together own over 5% of Bioniche shares. In the letter, the former Biovail...
BioCentury | Mar 25, 2013
Clinical News

Pimavanserin: Additional Phase III data

...scores vs. placebo (p=0.001) (see BioCentury, Dec. 3, 2012). In 2009, Acadia and former partner Biovail Corp....
BioCentury | Dec 17, 2012
Finance

Maple leaf windfall

...the past five years was 2010's $4.8 billion combination of two Canadian plays: specialty pharma Biovail Corp....
BioCentury | Dec 3, 2012
Clinical News

Pimavanserin: Phase III data

...eligible to enroll in an open-label safety extension study. In 2009, Acadia and former partner Biovail Corp....
BioCentury | Dec 3, 2012
Clinical News

Bupropion regulatory update

...Indianapolis, Indiana) markets duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), as Cymbalta . Biovail Corp....
...U.S. since 2003, retained rights in the rest of the world except in Canada, where Biovail...
BioCentury | Nov 28, 2012
Clinical News

Acadia jumps on Phase III pimavanserin data

...patients with PDP. In 2009, Acadia fell 66% to $2 after it and former partner Biovail Corp....
...vs. placebo. The companies said the placebo response in the trial was higher than expected. Biovail...
Items per page:
1 - 10 of 603